A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 4001
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : SVR
Long Form : sustained virological response
No. Year Title Co-occurring Abbreviation
2020 Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. DAAs, HP
2020 Defining the hepatitis C cure cascade in an Urban health system using the electronic health record. EHR, GHS, HCV
2020 Effects of eradication of HCV on cardiovascular risk and preclinical atherosclerosis in HIV/HCV-coinfected patients. BMKs, CIMT, CVR, DAA, LDL-C, PR, PWV, wk
2020 Hepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleeding. aHR
2020 Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. DAAs, EOT, IR
2020 Highly effective treatment response and well tolerability by all oral direct acting antivirals for chronic hepatitis C patients post organ transplantation. CHC, DAAs, IFN
2020 Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon. HCV, IFLN4
2020 Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy. DAA, HCC, HCV
2020 Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. HCV, PROs, SF-36
10  2020 Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. APRI, DAAs, HCC, HCV, PY
11  2020 Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir Ribavirin in the TOPAZ-I and TOPAZ-II Trials. RBV
12  2020 Metabolic Changes in Chronic Hepatitis C Patients Who Carry IFNL4-DeltaG and Achieve Sustained Virologic Response With Direct-Acting Antiviral Therapy. AST, CHC, DAA, HCV, HIV, LDL
13  2020 Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study. ---
14  2020 Performance of Acoustic Radiation Force Impulse Elastography for Staging Liver Fibrosis in Patients With Chronic Hepatitis C After Viral Eradication. ARFI, CHC, CI, LS
15  2020 Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. DAA, HCV, SOF
16  2020 Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study. DAAs
17  2020 Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment. DAA, GT
18  2020 Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/ paritaprevir/ ritonavir, dasabuvir + sofosbuvir + ribavirin. DAAs, RBV, SOF
19  2020 Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? DAAs, HCC, HCV, IFN
20  2020 Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. AEs, HCV, ITT, SAEs, SVR12
21  2020 Successful treatment of HBV, HCV, & HEV, with 12-week long use of tenofovir, sofosbuvir, daclatasvir, and ribavirin: A case report. DAA, HBV, HCC, HCV, HEV
22  2020 Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. AEs, ART, GT, LSM, SOF/DCV
23  2020 Sustained virological response by direct-acting antivirals reduces the recurrence risk of hepatitis C-related hepatocellular carcinoma after curative treatment. DAAs, HCC, HR, IFN, RFS
24  2020 Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma. DAA, HCC, HCV
25  2020 The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. RBV, SNPs
26  2020 Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia. INF, mITT, RBV, SOF
27  2019 A 12-week rescue therapy by PrOD-based regimen for advanced fibrotic genotype-1 CHC patients who failed to pegylated interferon plus ribavirin. CHC, PEG-IFN, PrOD, RBV
28  2019 A longitudinal study assessing depression in hepatitis C: Does gender play a role in the new-onset depression during interferon-alpha treatment? HCV, IFN-alpha, MDD
29  2019 A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study. HCV, HIV, LDV/SOF, UC
30  2019 Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. AOR, CI, DAA, HCC, HCV
31  2019 Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. DAA, GT, RBV, SOF, TF
32  2019 Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C. EV, HCC, LSM, SVR24
33  2019 Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy-Data From the German Hepatitis C-Registry (DHC-R). DAAs, DHC-R, EOT, HCV, ITT, LTFU, OST, PP
34  2019 Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. ABT, DAAs, FUW12, HCV
35  2019 APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? CKD, GTs, HCV
36  2019 APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. DAA, HBV, HCC, HCV, US
37  2019 Aspartate Aminotransferase-to-Platelet Ratio or Fibros-4 Index Predicts the Development of Hepatocellular Carcinoma in Chronic Hepatitis C Patients with Sustained Virologic Response to Interferon Therapy. APRI, CHC, FIB-4, HCC
38  2019 Association of serum interferon-lamda3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents. CHC, DAAs, HCC, HCV, IFN-lamda3
39  2019 Atorvastatin in Combination with Pegylated Interferon and Ribavirin Provided High Rate of Sustained Virological Response in Patients with Genotype 3 Hepatitis C Virus. BMI
40  2019 Automated Text Messaging With Patients in Department of Veterans Affairs Specialty Clinics: Cluster Randomized Trial. aTS, HCV, PRISM, VA
41  2019 B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. DAAs, DCV, HCC, HCV, LT, RBV, SOF
42  2019 Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program. HCV
43  2019 Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection. DAAs, dmax-IMT, HCV, IMT, LDL, sd
44  2019 CDR3 repertoire diversity of CD8+ T lymphocytes in patients with HCV. CDR3, EVR, HCV, MHC, RVR, TCR, VL
45  2019 Changes in Circulating Lysyl Oxidase-Like-2 (LOXL2) Levels, HOMA, and Fibrosis after Sustained Virological Response by Direct Antiviral Therapy. LOXL2, LSM, MetS
46  2019 Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. AUROC, BL, CSPH, FU, HVPG, IFN, PH, TE, VITRO
47  2019 Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study. DAAs, HCV
48  2019 Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. DAAs, HCV
49  2019 Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response. DAA, HCC, HCV
50  2019 Clinical characteristics and prognosis of HCC occurrence after antiviral therapy for HCV patients between sustained and non-sustained responders. HCC, HCV
51  2019 Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: a case-based review. CC, cCR, DAAs, HCV, HCV-GN, IS
52  2019 Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study. CHC, FU, HS, IFG, LTRs, T2D
53  2019 Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study. EOT, HCV
54  2019 Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. B-NHL, CV, ICs, MC
55  2019 Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4. HCV, RASs
56  2019 Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naive patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. OPrD
57  2019 Comparing interferon-free with interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox. ---
58  2019 Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance. aa, COI, DAAs, HCC, HCV-1
59  2019 Control of HCV Infection by Natural Killer Cells and Macrophages. HCV, IFN-alpha, NK
60  2019 Cost Effectiveness of Hepatocellular Carcinoma SurveillanceAfter a Sustained Virologic Response to Therapyin Patients With Hepatitis C Virus Infection and Advanced Fibrosis. HCC, HCV, ICERs, QALYs
61  2019 Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. CC, DC, GT, HCC, ICERs, IFN, LT, NC, QALY, TE, TN, TVR
62  2019 Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. DOT, GT, HEP-CE, ICERs, OAT, SIT
63  2019 Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West. DAAs, IFN, PSM
64  2019 Cytokine balance is restored as patient-reported outcomes improve in patients recovering from chronic hepatitis C. BDI-II, CHC, CLDQ-HCV, FACIT-F, FSS, PROs, SF-36
65  2019 Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. ASV, DCV, ETR, HCV, NS5A, RVR, SVR12
66  2019 Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. DAAs, HCV, OCI, PBMC, PR
67  2019 Developments in the treatment of HCV genotype 3 infection. DAAs, GTs, HCV
68  2019 Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. ARFI, DAAs, LSMs
69  2019 Direct Acting Antiviral Treatment for Patients with End-Stage Kidney Disease with Acute HCV Infection. DAA, ESKD, HCV
70  2019 Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. AD, DAAs, DCV, GT, HCV, SIM, SOF
71  2019 Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. DAA, HCC
72  2019 Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community. ---
73  2019 Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective. CHC, DAAs, DCV, SOF, SVR12, TE, TN
74  2019 Direct-Acting Antiviral Treatment Failure Among Hepatitis C and HIV-Coinfected Patients in Clinical Care. CrI, DAA, HCV, OR, ORs
75  2019 Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan. CHC, DAAs, HCC, IFN, PEG-IFN, RFS
76  2019 Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy. DAAs, GLE/PIB, GZP/RLB, IFN/RBV, SmPC, SOF/VEL
77  2019 Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study. APRI, DCV/ASV, FI, GT1b, HCV, LSM, NS5A, RAS
78  2019 Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection. DAAs, EOT, HCV, IFN, ISGs, TW, VF
79  2019 Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Who Achieved Sustained Virologic Response. HCC, HCV
80  2019 Effect of Combined HCV Therapy on Natural Killer Cell Activity. HCV, IFN, MFI, NCRs, NK
81  2019 Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial. AVT, CNIs, CsA, DAA, HCV, LDLT, LT, RBV, TAC
82  2019 Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study). ---
83  2019 Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis. HCV, HOMA, IFN, IR
84  2019 Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital. HCV
85  2019 Effect of sofosbuvir and daclatasvir on lipid profile, glycemic control and quality of life index in chronic hepatitis C, genotype 3 patients. LDL
86  2019 Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. DAA, DCV, GT, RAS, RBV, SOF, VEL
87  2019 Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective. CHC, ICER, LYs, QALYs
88  2019 Effectiveness and safety of chronic hepatitis C treatment with direct-acting antivirals in patients with rheumatic diseases: A case-series. DAA, HCV, RA, RDs
89  2019 Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. DAA, GT, HCV, SVR12
90  2019 Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C. GT, LDV/SOF
91  2019 Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. CI, LVD, SOF
92  2019 Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response. CI, DAAs, LSM
93  2019 Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. CIs, DAA, HIV
94  2019 Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy. HCV, LDV/SOF, OAT, PWID, SOF/VEL
95  2019 Effects of Age on Treatment of Chronic Hepatitis C with Direct Acting Antivirals. CHC
96  2019 Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study. CHC, PEG-IFN-alpha, RBV
97  2019 Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. HCV-1b, NS5A, RASs
98  2019 Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis. CI, DAA, HCV, RVR
99  2019 Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis. AEs, DAAs, RRs
100  2019 Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. CKD, DAAs, EBR/GZR, HCV, SVR12